Phase 2CompletedAge-related condition

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause

A Phase 2, Randomized, Placebo-controlled, 12-week, Double-blind Study to Assess the Efficacy and Safety of Fezolinetant 45 mg in Chinese Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Sponsor
Astellas Pharma Global Development, Inc. (Industry)
Enrollment
150 enrolled
Conditions
Hot Flashes
Interventions
Fezolinetant; Placebo
Ages
adults, older adults
Registry
NCT06812754

Full record on ClinicalTrials.gov

From the registry

Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed. The goal of this study is to confirm if fezolinetant helps reduce hot flashes in Chinese women going through menopause. This study will also confirm the safety of fezolinetant and how well the women cope with (tolerate) the treatment. The women will take 1 tablet of the study medicine either fezolinetant or placebo once a day for up to 12 weeks. This is decided by chance alone. The placebo looks like fezolinetant but will not have any medicine in it. Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes and night sweats. The women will record this information before, during and after taking the study treatment. During the study, the women will visit the study clinic several times. At each visit they will be asked if they had any medical problems. The women will have…

Primary outcomes

  • Mean change in the frequency of moderate to severe Vasomotor Symptoms (VMS) from baseline to week 12

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Started

  5. Registered